EICHOR
● Not Yet Recruiting
Aspirin-Free Strategy After 3-6 Month Dual Antiplatelet Therapy in Acute Coronary Syndrome
Condition: Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) · Dual Anti-platelet Therapy · Sponsor: Assiut University
About this study
This randomized controlled trial aims to evaluate the safety and efficacy of an aspirin-free strategy after 3-6 months of dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome (ACS) who have undergone complete coronary revascularization by percutaneous coronary intervention (PCI). Participants will be randomized to either discontinue aspirin and continue P2Y12 inhibitor monotherapy or continue standard antiplatelet therapy. The primary objective is to determine whether the aspirin-free strategy reduces bleeding events without increasing ischemic events during follow-up.
This description comes directly from the study's public registry record.
Talk to the study team
Asmaa Sayed Shaban, MBBch · +2013840163 · asmaasayed641@yahoo.com
Always discuss trial participation with your own doctor first.
Locations (1)
| Assiut University Hospital | Asyut, Asyut Governorate, Egypt | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07736196